证券代码：300723 证券简称：一品红 公告编号：2026-012 一品红药业集团股份有限公司 关于全资子公司创新药 APH03571 片获得临床试验注册申请受理的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 近日，一品红药业集团股份有限公司（以下简称"公司"）全资子公司广州 一品红制药有限公司自主研发的创新药物 APH03571 片的药物临床试验申请获得 国家药品监督管理局受理，并收到《受理通知书》。现将相关情况公告如下： 一、《受理通知书》主要内容 | 药品名称 | | 申请事项 | 适应症 | 规格 | 受理号 | | --- | --- | --- | --- | --- | --- | | | | | 用于携带 FLT3 突变的复发性 | 25mg | CXHL2600373 | | | | 境内生产药品注 | | | | | APH03571 | 片 | | 或难治性急性髓系白血病 | | | | | | 册临床试验 | | 100mg | CXHL2600374 | | | | | （AML）成人患者 | | | 根据《中华人民共和国行 ...

证券代码：300723 证券简称：一品红 公告编号：2026-011 一品红药业集团股份有限公司 关于公司回购股份完成暨股份变动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一品红药业集团股份有限公司（以下简称"公司"）于 2025 年 12 月 15 日 召开第四届董事会第十四次会议审议通过了《关于回购公司股份方案的议案》， 同意公司使用自有资金及/或自筹资金以集中竞价方式回购公司部分已发行的人 民币普通股（A 股）股票用于维护公司价值及股东权益。 本次用于回购的资金总额为不低于人民币 10,000 万元且不超过人民币 20,000 万元。回购价格不超过人民币 70.00 元/股（含）。回购股份的实施期限为 自公司董事会审议通过本次回购方案之日起三个月内。本次回购股份方案在董事 会决策权限之内，无需提交股东会审议。具体情况详见公司分别于 2025 年 12 月 16 日、2025 年 12 月 17 日披露于巨潮资讯网（http://www.cninfo.com.cn）的 《关于回购公司股份方案的公告》（公告编号：2025-089）、《回购报告书》 ...

Core Viewpoint - Yipinhong Pharmaceutical is undergoing a strategic transformation, focusing on the innovative drug AR882 for gout while divesting its stake in Arthrosi Therapeutics for $1.5 billion to secure cash flow and concentrate on the Chinese market [3][11][30]. Group 1: Strategic Decisions - The company sold its stake in Arthrosi Therapeutics for a total value of up to $1.5 billion, which includes an upfront payment of $950 million and potential milestone payments of up to $550 million [10][11]. - Despite selling its overseas rights, Yipinhong retains 100% rights for AR882 in Greater China, allowing it to operate as the exclusive operator in this region while also securing global supply rights [11][30]. - The decision to divest was influenced by the need to alleviate cash flow pressures, as the company has faced two consecutive years of losses, with a projected net loss of between 313 million to 442 million yuan for 2025 [13][24]. Group 2: Product Development and Market Potential - AR882 is positioned as a best-in-class gout treatment, with clinical data showing significant reductions in serum uric acid levels and gout stone dissolution rates [7][8]. - The drug's clinical trials have shown promising results, with a 49.4% reduction in serum uric acid for difficult-to-treat patients after 12 months [7]. - The company has completed the enrollment of 680 patients in its domestic Phase III clinical trials, with key data expected to be released in the second quarter of 2026 [8][32]. Group 3: AI Drug Development - Yipinhong is also investing in AI drug development, partnering with AlphaMol to leverage AI in drug discovery, particularly targeting GPCRs, which are crucial drug targets [17][20]. - The AI technology is expected to significantly reduce drug development timelines and costs, enhancing the company's research efficiency [20]. - The collaboration with AlphaMol has already yielded results, with the approval of AM-001 for clinical trials in both China and the US [19]. Group 4: Market Environment and Challenges - The Chinese gout patient population is large and growing, creating a significant market opportunity for AR882, especially among patients with treatment-resistant gout stones [30]. - However, the company faces challenges from increasing competition in the gout treatment market and the need to navigate the evolving healthcare reimbursement landscape in China [32][30]. - The company aims to achieve profitability by 2026, with the success of AR882's commercialization being critical to this goal [35][39].

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology industry [1]. Core Insights - The National People's Congress has designated innovative drugs as a "new emerging pillar industry," indicating a strategic shift for the biopharmaceutical sector from a nurturing phase to a core engine of economic growth [16][17]. - As of March 6, 2026, the total value of business development (BD) contracts for Chinese innovative drugs has reached $56.8 billion, with an upfront payment of $3.3 billion, representing 41% of the total for 2025 and exceeding the total for 2024 [17][21]. - Despite significant stock price corrections from 2025 highs, the fundamentals of quality companies remain solid, and the long-term growth logic for innovative drug exports is still intact [21]. Summary by Sections Industry Trends - The A-share pharmaceutical index has seen a year-to-date decline of 2.42%, underperforming the CSI 300 by 1.02% [9]. - The Hang Seng Healthcare Index has outperformed the Hang Seng Technology Index by 0.97% year-to-date [9]. R&D Progress and Company Dynamics - Recent approvals include HSK31679 for non-alcoholic fatty liver disease and the GLP-1 receptor agonist Enogratide, marking significant advancements in innovative drug development [17]. - The report highlights specific companies to watch, including: - PD1 PLUS: Sangamo Therapeutics, CanSino Biologics, Innovent Biologics, and Zai Lab [12]. - ADC: I-Mab Biopharma, Kelun-Biotech, and Baiyue Tianheng [12]. - Small nucleic acids: Frontier Biotechnologies, Fuyuan Pharmaceutical, and Yuyuan Pharmaceutical [12]. Market Performance - The report notes that the pharmaceutical index's price-to-earnings ratio is currently at 36.18, which is 2.24 times lower than the historical average [9]. - The report identifies top-performing stocks for the week, including Yahu Pharmaceutical (+40.65%) and Duoyi Pharmaceutical (+30.81%), while highlighting significant declines in stocks like Haixiang Pharmaceutical (-15.06%) and Furu Medical (-13.07%) [9].

证券代码：300723 证券简称：一品红 公告编号：2026-010 一品红药业集团股份有限公司 关于回购公司股份的进展公告 一、股份回购的进展情况 截至 2026 年 2 月 28 日，公司通过回购专用证券账户以集中竞价交易方式累 计回购公司股份数量为 316.22 万股，占公司总股本的 0.70%，最高成交价为 37.85 元/股，最低成交价为 32.15 元/股，成交均价为 34.78 元/股，已使用资金总额为 10,998.44 万元（不含手续费）。公司上述回购实施情况符合既定回购方案及相关 法律法规的要求。 二、其他说明 本次回购股份的时间、回购股份数量及集中竞价交易的委托时段等符合《上 市公司股份回购规则》《深圳证券交易所上市公司自律监管指引第 9 号——回购 股份》等相关规定，具体如下： 1、公司不得在下列期间内回购公司股票： （1）自可能对本公司证券及其衍生品种交易价格产生重大影响的重大事项 发生之日或者在决策过程中，至依法披露之日内； 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一品红药业集团股份有限公司（以下简称"公司"）于 2025 ...

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology sector [1] Core Insights - The upcoming adjustment of the National Essential Medicines List (NEML) is expected to benefit traditional Chinese medicine (TCM) stocks, with a focus on companies like Zhaoli Pharmaceutical, Fangsheng Pharmaceutical, and Panlong Pharmaceutical [2][17][22] - The report ranks sub-sectors in the following order of preference: innovative drugs > research services > CXO > TCM > medical devices > pharmacies [2][11] - Historical data indicates that products included in the NEML tend to experience significant sales growth, as seen with Zhaoli Pharmaceutical's Wuling Capsule, which saw sales growth rates increase from -12.82% in 2017 to 32.52% in 2021 after being included in the NEML [19][22] Summary by Sections Investment Highlights - The report suggests focusing on TCM stocks due to the imminent NEML adjustments, recommending Zhaoli Pharmaceutical, Fangsheng Pharmaceutical, and Panlong Pharmaceutical [2][17] - The report emphasizes the importance of the NEML adjustments, which have not occurred in eight years, and the potential for TCM products to gain market share [22] R&D Progress and Company Dynamics - Recent approvals and submissions include Sanofi's Dupilumab for new indications and GSK's hepatitis B therapy application in Japan [5] - The report highlights various companies across different therapeutic areas, including innovative drugs, ADCs, and small nucleic acids, suggesting a diversified investment approach [13][22] Market Performance - The A-share pharmaceutical index has shown a year-to-date increase of 3.0%, with notable performances from specific stocks such as Aidi Te (+36.9%) and Wanze Shares (+27.5%) [10] - The report notes that the medical sector has seen varied performance, with biopharmaceuticals and medical devices showing positive trends, while chemical pharmaceuticals and medical services have faced declines [10]

| | | 续输注不可超过 24h。 | | | --- | --- | --- | --- | | | | 适用于 1 岁以上儿童哮喘的预防和长期治 | | | | | 疗，包括预防白天和夜间的哮喘症状，治疗 | | | | 孟鲁司特钠 | 对阿司匹林敏感的哮喘患者以及预防运动 | | | 8 | 颗粒 | 诱发的支气管收缩和减轻过敏性鼻炎引起 | 0.5g:4mg | | | | 的症状（ 2 岁至 5 岁儿童的季节性过敏性 | | | | | 鼻炎和常年性过敏性鼻炎）。 | | | | | 可用于治疗成年人（≥18 岁）由金黄色葡萄 球菌、铜绿假单胞菌、粘质沙雷氏菌、大肠 | | | | | 埃希菌、肺炎克雷伯杆菌、流感嗜血杆菌、 | | | | | 肺炎链球菌等细菌的敏感菌株所引起的下 | | | | | 列轻、中、重度感染，包括：医院获得性肺 | | | 9 | 左氧氟沙星 | 炎、社区获得性肺炎、急性细菌性鼻窦炎、 | 0.5g | | | 片 | 慢性支气管炎的急性细菌性发作、复杂性皮 | | | | | 肤及皮肤结构感染、非复杂性皮肤及皮肤软 | | | | | 组织感染、慢性细菌性前列腺炎、 ...

Core Viewpoint - The company Yipinhong (300723.SZ) has participated in the national procurement bidding for drugs whose agreements have expired, with 15 drug varieties proposed for selection in the upcoming procurement, which could positively impact its future operations and market presence [1] Group 1: Procurement Participation - The company's wholly-owned subsidiary, Guangzhou Yipinhong Pharmaceutical Co., Ltd., recently took part in the national procurement bidding organized by the procurement office for drugs with expired agreements [1] - The procurement office announced on February 10, 2026, that 15 drug varieties from the company are proposed for selection in this procurement [1] Group 2: Financial Impact - The total sales revenue for the 15 selected drug varieties is projected to be 228 million yuan for the year 2024, accounting for 15.75% of the company's total revenue for that year [1] - For the first three quarters of 2025, the projected sales revenue for these drugs is 157 million yuan (unaudited), representing 19.25% of the company's revenue for that period [1] Group 3: Future Implications - If procurement contracts are signed and implemented, it will further increase product sales, enhance market share, and improve the company's brand image, positively influencing its future business development [1]

Core Viewpoint - The company announced that its wholly-owned subsidiary, Guangzhou Yipinhong Pharmaceutical Co., Ltd., participated in the national organized procurement for drugs whose agreements have expired, with 15 drug varieties proposed for selection in the upcoming procurement [1] Group 1 - The subsidiary engaged in the bidding process organized by the national procurement office for drugs with expired agreements [1] - The procurement results are set to be publicly announced on February 10, 2026 [1] - A total of 15 drug varieties from the company are proposed for selection in this procurement [1]

Core Viewpoint - The company Yipinhong (300723) has stated that it will determine its profit distribution policy and plan in accordance with relevant laws and regulations, including the Company Law, Enterprise Accounting Standards, and the Guidelines for Listed Companies on Cash Dividends [1] Group 1 - The company will adhere to the Company Law and relevant accounting standards when establishing its profit distribution policy [1] - The profit distribution plan will also comply with the Guidelines for Listed Companies on Cash Dividends [1] - The company will follow its Articles of Association in determining the profit distribution [1]